Drugs / DS102
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial · 1 met primary | ||||||
| Phase 1 | NCT02673593 | Jul → Dec 2015 | — | DS Biopharma | Completed | Met primary |
| Phase 23 trials · 1 missed | ||||||
| Phase 2 | NCT04365400 | Oct 2020 → May 2022 | hypertriglyceridemia, type 2 diabetes mellitus | Afimmune | Terminated | Missed primary |
| Phase 2 | NCT03452540 | Nov 2018 → Jun 2019 | alcoholic hepatitis | Afimmune | Terminated | No outcome recorded |
| Phase 2 | NCT03414541 | Sep 2017 → Jan 2019 | chronic obstructive pulmonary disease | Afimmune | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2021-08-26 | Afimmune | Results Afimmune’s Epeleuton shows large decreases in viral load and pathological changes in COVID-19 study afimmune.com ↗
Epeleuton at clinically relevant doses decreased viral load and replication as evidenced by significant and dose-dependent decreases of viral titres and SARS-CoV-2 RNA in throats, nasal turbinates and lungs. |
| 2015-12-18 | Afimmune | Results Afimmune announces successful completion of a Phase I safety study with bioactive lipid DS102 afimmune.com ↗
The study confirmed that following both single and multiple oral doses over 28 days, DS102 was safe and well tolerated, thereby successfully meeting the study’s primary safety objective. |
All press releases naming this drug 11 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DS102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04365400 ↗ |
| Known as | Epeleuton | “DS102 Epeleuton capsules” NCT04365400 ↗ |
| Route | Oral | “DS102 capsules will be orally administered for up to 4 weeks” NCT02673593 ↗ |